...through 15 sites, will start by testing SM-88...
...care arms in metastatic pancreatic cancer patients. SM-88...

...preliminary data from the open-label Phase II Tyme-88-Panc trial. The company said that once-daily oral SM-88...
...received SM-88 remained alive. By line of therapy, three of four (75%) patients who received SM-88...
...OS) Status: Preliminary Phase II data Milestone: Complete Phase II (12/2019) Chris Lieu Oral SM-88, SM88, SM-88, TYME-88 American...

...open-label Phase I trial in 30 patients with progressive metastatic cancer showing that SM-88 (TYME-88, SM88...
...patients achieving stable disease, SM-88 led to a median overall survival (OS) of 29 months. SM-88...
...in pancreatic cancer. Tyme Technologies Inc. (NASDAQ:TYME), New York, N.Y. Product: SM-88 ( TYME-88 , SM88...

...with refractory pancreatic cancer in an open-label, U.S. Phase I trial showing that TYME-88 (SM-88, SM88...
...of TYME-88 to treat refractory pancreatic cancer. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Product: TYME-88...
...refractory pancreatic cancer. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Product: TYME-88 ( SM-88 , SM88...

...recurrent, non-metastatic prostate cancer in a 6-month Phase Ib/II trial showing that oral TYME-88 (SM-88, SM88...
...PFS, the effect of TYME-88 on CTCs, PSA doubling time, biomarkers, safety and patient-reported outcomes. TYME-88...
...expected in 2H18. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Product: TYME-88 ( SM-88 , SM88...

...Tyme began an open-label, dose-escalation, dose-expansion, U.S. Phase Ib/II trial to evaluate SM-88 in up to...
...who failed previous androgen deprivation therapy. Tyme Inc. (OTCQB:TYMI), New York, N.Y. Product: SM88 , SM-88...

...merger, raising $6.8 million through the sale of 2.7 million shares at $2.50. Tyme Inc.’s SM-88...
...comprises four undisclosed marketed drugs that alter the susceptibility of cancer cells to oxidative stress. SM-88...